Rheumatoid arthritis: transarterial microembolization for refractory localized joint inflammation.

Skeletal RadiolMay 18, 2026 (epub)

You-Chien Lin, Jia-Min Wu, Cheng-Chun Lee et al.

✦ AI-curated · Sources linked

Case in brief

A 31-year-old woman with rheumatoid arthritis affecting her elbow, knee, and ankle experienced persistent localized joint pain despite systemic therapy. She underwent selective transarterial microembolization targeting neovascularization, which resulted in decreased hypervascularity on post-embolization angiography. Over 12 months, her pain and function improved, with MRI showing reduced synovial proliferation and edema, while her systemic therapy remained unchanged.

Diagnostic / clinical pearl

Transarterial microembolization may be a beneficial adjunct for managing refractory localized joint inflammation in rheumatoid arthritis, particularly when systemic therapies are insufficient.

Why it matters

This case highlights the potential of targeted interventions like transarterial microembolization in addressing localized symptoms of rheumatoid arthritis, warranting further investigation into its efficacy and safety.

Source

Published in Skeletal Radiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Rheumatology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.